Comparison of Caspase Genes for the Induction of Apoptosis Following Gene Delivery

Overview

Journal Mol Biotechnol

Publisher Springer

Specialties Biotechnology
Molecular Biology

Date 2008 Dec 11

PMID 19067254

Citations 4

Authors

Xiujuan Zhang

Curlicia Turner

W T Godbey

Affiliations

Soon will be listed here.

Abstract

The polycation poly(ethylenimine) (PEI) was used to deliver the plasmids coding for various combinations of caspases to Cox-2 overexpressing cancer cell lines. It was found that the expression of the delivered genes, controlled by the Cox-2 promoter, correlated with the expression of the endogenous Cox-2 gene in each cell line in a relatively linear manner. Among the various caspase combination regimens, the combination of caspase 3 plus caspase 9 proved to be the most effective because of an apparent synergy between the two gene products, and produced phosphatidylserine flipping in addition to fragmentation of genomic DNA. Caspase 1 appeared to work independently of either caspases 3 or 9, as no synergistic effect was observed. Transfections with genes coding for granzyme B and caspase 8 yielded a lesser amount of cell death. The delivery of a combination of caspase genes could be readily moved to in vivo research of bladder and colon cancer treatments, and holds great applicability to a wide array of additional tumor types.

Citing Articles

Exogenous Introduction of Initiator and Executioner Caspases Results in Different Apoptotic Outcomes.

Anson F, Thayumanavan S, Hardy J JACS Au. 2021; 1(8):1240-1256.

PMID: 34467362 PMC: 8385707. DOI: 10.1021/jacsau.1c00261.

Preclinical evaluation of VAX-IP, a novel bacterial minicell-based biopharmaceutical for nonmuscle invasive bladder cancer.

Tsuji S, Chen X, Hancock B, Hernandez V, Visentin B, Reil K Mol Ther Oncolytics. 2016; 3:16004.

PMID: 27119118 PMC: 4824562. DOI: 10.1038/mto.2016.4.

Analysis of promoters and expression-targeted gene therapy optimization based on doubling time and transfectability.

Dobek G, Zhang X, Balazs D, Godbey W FASEB J. 2011; 25(9):3219-28.

PMID: 21602450 PMC: 6188461. DOI: 10.1096/fj.11-185421.

Proteases as therapeutics.

Craik C, Page M, Madison E Biochem J. 2011; 435(1):1-16.

PMID: 21406063 PMC: 4503466. DOI: 10.1042/BJ20100965.

References

Rajnakova A, Moochhala S, Goh P, Ngoi S . Expression of nitric oxide synthase, cyclooxygenase, and p53 in different stages of human gastric cancer. Cancer Lett. 2001; 172(2):177-85. DOI: 10.1016/s0304-3835(01)00645-0. View

Mohammed S, Knapp D, Bostwick D, Foster R, Khan K, Masferrer J . Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res. 1999; 59(22):5647-50. View

Hetts S . To die or not to die: an overview of apoptosis and its role in disease. JAMA. 1998; 279(4):300-7. DOI: 10.1001/jama.279.4.300. View

Moriuchi S, Oligino T, Krisky D, Marconi P, Fink D, Cohen J . Enhanced tumor cell killing in the presence of ganciclovir by herpes simplex virus type 1 vector-directed coexpression of human tumor necrosis factor-alpha and herpes simplex virus thymidine kinase. Cancer Res. 1998; 58(24):5731-7. View

Kutchera W, Jones D, Matsunami N, Groden J, McIntyre T, Zimmerman G . Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci U S A. 1996; 93(10):4816-20. PMC: 39362. DOI: 10.1073/pnas.93.10.4816. View

Martin S, Reutelingsperger C, McGahon A, Rader J, van Schie R, LaFace D . Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med. 1995; 182(5):1545-56. PMC: 2192182. DOI: 10.1084/jem.182.5.1545. View

Eissa S, Seada L . Quantitation of bcl-2 protein in bladder cancer tissue by enzyme immunoassay: comparison with Western blot and immunohistochemistry. Clin Chem. 1998; 44(7):1423-9. View

Strausberg R, Feingold E, Grouse L, Derge J, Klausner R, Collins F . Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci U S A. 2002; 99(26):16899-903. PMC: 139241. DOI: 10.1073/pnas.242603899. View

Vile R, Russell S, Lemoine N . Cancer gene therapy: hard lessons and new courses. Gene Ther. 2000; 7(1):2-8. DOI: 10.1038/sj.gt.3301084. View

10.

Zhang G, Gurtu V, Kain S, Yan G . Early detection of apoptosis using a fluorescent conjugate of annexin V. Biotechniques. 1997; 23(3):525-31. DOI: 10.2144/97233pf01. View

11.

Moffatt S, Wiehle S, Cristiano R . A multifunctional PEI-based cationic polyplex for enhanced systemic p53-mediated gene therapy. Gene Ther. 2006; 13(21):1512-23. DOI: 10.1038/sj.gt.3302773. View

12.

Trifan O, Hla T . Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med. 2003; 7(3):207-22. PMC: 6741314. DOI: 10.1111/j.1582-4934.2003.tb00222.x. View

13.

Eastham J, Chen S, Sehgal I, Yang G, Timme T, Hall S . Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum Gene Ther. 1996; 7(4):515-23. DOI: 10.1089/hum.1996.7.4-515. View

14.

Nicholson D, Thornberry N . Caspases: killer proteases. Trends Biochem Sci. 1997; 22(8):299-306. DOI: 10.1016/s0968-0004(97)01085-2. View

15.

Koopman G, Reutelingsperger C, Kuijten G, Keehnen R, Pals S, van Oers M . Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 1994; 84(5):1415-20. View

16.

Shirahama T, Sakakura C . Overexpression of cyclooxygenase-2 in squamous cell carcinoma of the urinary bladder. Clin Cancer Res. 2001; 7(3):558-61. View

17.

Jin L, Zeng H, Chien S, Otto K, Richard R, Emery D . In vivo selection using a cell-growth switch. Nat Genet. 2000; 26(1):64-6. DOI: 10.1038/79194. View

18.

Fan T, Han L, Cong R, Liang J . Caspase family proteases and apoptosis. Acta Biochim Biophys Sin (Shanghai). 2005; 37(11):719-27. DOI: 10.1111/j.1745-7270.2005.00108.x. View

19.

Kagawa S, He C, Gu J, Koch P, Rha S, Roth J . Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res. 2001; 61(8):3330-8. View

20.

Yamabe K, Shimizu S, Ito T, Yoshioka Y, Nomura M, Narita M . Cancer gene therapy using a pro-apoptotic gene, caspase-3. Gene Ther. 2000; 6(12):1952-9. DOI: 10.1038/sj.gt.3301041. View